<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358875</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-303</org_study_id>
    <nct_id>NCT03358875</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC</brief_title>
  <official_title>A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that BGB-A317 will improve overall survival in subjects
      with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or
      third-line treatment setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, multicenter Phase 3 study in adult patients with
      histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous
      or non-squamous) who have disease progression during or after a platinum-containing regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 34 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>Up to 34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life(HRQoL)</measure>
    <time_frame>Up to 34 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) graded according to NCI-CTCAE, v4.03.</measure>
    <time_frame>Up to 34 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>BGB-A317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-A317, 100 mg per vial, 200mg IV, Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 IV Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>BGB-A317</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Able to provide written informed consent and can understand and comply with the
        requirements of the study.

          1. Age18 years.

          2. Signed Informed Consent Form.

          3. Histologically confirmed locally advanced or metastatic (Stage IIIB or IV) NSCLC with
             disease progression during or following treatment with at least one
             platinum-containing regimen, but no more than 2 lines of systemic therapy.

          4. Subjects must be able to provide fresh or archival tumor tissues for central
             assessment of PD-L1 expression in tumor cells.

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

          6. Adequate hematologic and end-organ function.

        Exclusion Criteria:

          1. Prior therapies of docetaxel or treatment targeting PD-1, PD-L1 or CTLA-4.

          2. Harboring EGFR sensitizing mutation or ALK gene translocation.

          3. Unresolved acute effects of prior therapy of Grade 2-5, except for AEs (e.g. alopecia,
             neuropathy, specific lab abnormalities) not constituting a likely safety risk.

          4. History of severe hypersensitivity reactions to other mAbs.

          5. History of interstitial lung disease or non-infectious pneumonitis, except for those
             induced by radiation therapies.

          6. With uncontrollable pleural effusion, pericardial effusion, or clinically significant
             ascites requiring interventional treatment.

          7. Diagnosis of other malignancies with some exceptions.

          8. Active infection requiring systemic treatment, known HIV infection, subjects with
             untreated chronic hepatitis B or chronic HBV, active vaccination treatment.

          9. Insufficient cardiac functions and other underlying unfavorable conditions.

         10. Prior allogeneic stem cell transplantation or organ transplantation.

         11. Active autoimmune diseases or history of autoimmune diseases that may relapse should
             be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Cao</last_name>
    <phone>+86 10 5895 8000</phone>
    <email>ClinicalTrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziping WANG</last_name>
      <phone>8613301212676</phone>
      <email>wangzp2007@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi HU</last_name>
      <phone>8613911031186</phone>
      <email>huyi0401@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhe LIU</last_name>
      <phone>8613651392121</phone>
      <email>lza@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan YU</last_name>
      <phone>8613904505825</phone>
      <email>gpyuyan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunpeng LIU</last_name>
      <phone>8613898865122</phone>
      <email>cmu_trial@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caicun ZHOU</last_name>
      <phone>8613301825532</phone>
      <email>caicunzhoudr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dingzhi HUANG</last_name>
      <phone>8613116047308</phone>
      <email>ec_tjich@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinmin YU</last_name>
      <phone>8613705718617</phone>
      <email>2231295153@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

